Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 24;23(6):385-400.
doi: 10.1093/ijnp/pyaa018.

Reviewing the Potential of Psychedelics for the Treatment of PTSD

Erwin Krediet  1   2 , Tijmen Bostoen  1   2 , Joost Breeksema  1   3 , Annette van Schagen  2 , Torsten Passie  4   5 , Eric Vermetten  1   2   6
Affiliations
Review

Reviewing the Potential of Psychedelics for the Treatment of PTSD

Erwin Krediet et al. Int J Neuropsychopharmacol. .

Abstract

There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not just novel compounds but novel approaches for the treatment of PTSD. A promising new approach involves the use of psychedelic drugs. Within the past few years, 2 psychedelics have received breakthrough designations for psychiatric indications from the US Food and Drug Administration, and several psychedelics are currently being investigated for the treatment of PTSD. This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids. We describe the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD. Each compound provides unique qualities for the treatment of PTSD, from their use to rapidly target symptoms to their use as adjuncts to facilitate psychotherapeutic treatments. Several questions are formulated that outline an agenda for future research.

Keywords: MDMA; PTSD; cannabinoids; ketamine; psychedelics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akram H, Mokrysz C, Curran HV (2019) What are the psychological effects of using synthetic cannabinoids? A systematic review. J Psychopharmacol 33:271–283. - PubMed
    1. Albott CS, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, Thuras P, Batres-y-Carr TM, Wels J, Shiroma PR (2018) Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry 79:1–8. - PubMed
    1. Aust S, Gärtner M, Basso L, Otte C, Wingenfeld K, Chae WR, Heuser-Collier I, Regen F, Cosma NC, van Hall F, Grimm S, Bajbouj M (2019) Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Eur Neuropsychopharmacol 29:529–538. - PubMed
    1. Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX (2018) Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cerebral Cortex 28:3939–3950. - PMC - PubMed
    1. Bastiaans J. (1983) Mental liberation facilitated by the use of hallucinogenic drugs. In: Psychedelic Reflections (Grinspoon L, Bakalar BB, eds), pp 143–152. New York: Human Science Press.

Publication types

MeSH terms